Form D · Biotechnology
Droplet Biosciences, Inc.
Cambridge, MA · CIK 0001847243
Offering snapshot reported Dec 13, 2023 · SEC filing
- Reported sold
- $7.61M Offering amount: $14.1M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 28, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 13, 2023 | Initial | $7,613,974 | No comparison | 21 | SEC filing |
| May 28, 2021 | Initial | $5,348,980 | No comparison | 30 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-499503
Includes $3,764,175 in principal and interest of converting indebtedness
Source: Form D, filed Dec 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aadel Chaudhuri | Director, Executive |
| Ann De Witt | Director |
| Stanley Lapidus | Director |
| Rachel Sha | Director |
| Theresa Tribble | Director, Executive |
| Jose Zevallos | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
750 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139